PRKN and Parkinson disease: Interestingly, a loss of the Drosophila LRRK2 homolog also led to an activation of 4E-BP, acting to suppress Pinkl and Parkin pathology in these flies, suggesting that the pharmacological stimulation of 4E-BP activity may hold potential for PD therapy, especially in comparison to LRRK2, which has been traditionally difficult to selectively target without side effects.